Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway

被引:57
作者
Cao, Yongheng
Kamioka, Yuji
Yokoi, Norihide
Kobayashi, Toshiyuki
Hino, Okio
Onodera, Masafumi
Mochizuki, Naoki
Nakae, Jun
机构
[1] Kobe Univ, Grad Sch Med, Div Diabet Digest & Kidney Dis, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Natl Cardiovasc Ctr, Res Inst, Dept Struct Analysis, Suita, Osaka 5658565, Japan
[3] Kobe Univ, Grad Sch Med, Div Cell & Mol Med, Kobe, Hyogo 6500017, Japan
[4] Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Toshima Ku, Tokyo 1708455, Japan
[5] Univ Tsukuba, Grad Sch Comprehens Human Sci, Adv Biomed Appl, Tsukuba, Ibaraki 3058575, Japan
关键词
D O I
10.1074/jbc.M608116200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Both TSC2 ( tuberin) and forkhead transcription factor FoxO1 are phosphorylated and inhibited by Akt and play important roles in insulin signaling. However, little is known about the relationship between TSC2 and FoxO1. Here we identified TSC2 as a FoxO1-binding protein by using a yeast two-hybrid screening with a murine islet cDNA library. Among FoxOs, only FoxO1 can be associated with TSC2. The physical association between the C terminus of TSC2 ( amino acids 1280-1499) and FoxO1 degrades the TSC1-TSC2 complex and inhibits GTPase-activating protein activity of TSC2 toward Rheb. Overexpression of wild type FoxO1 enhances p70 S6K phosphorylation, whereas overexpression of TSC2 can reverse these effects. Knockdown of endogenous FOXO1 in human vascular endothelial cells decreased phosphorylation of p70 S6K. Prolonged overexpression of wild type FoxO1 enhanced phosphorylation of serine 307 of IRS1 and decreased phosphorylation of Akt and FoxO1 itself even in the presence of serum. These data suggest a novel mechanism by which FoxO1 regulates the insulin signaling pathway through negative regulation of TSC2 function.
引用
收藏
页码:40242 / 40251
页数:10
相关论文
共 64 条
[1]
FoxOs at the crossroads of cellular metabolism, differentiation, and transformation [J].
Accili, D ;
Arden, KC .
CELL, 2004, 117 (04) :421-426
[2]
The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination [J].
Benvenuto, G ;
Li, SW ;
Brown, SJ ;
Braverman, R ;
Vass, WC ;
Cheadle, JP ;
Halley, DJJ ;
Sampson, JR ;
Wienecke, R ;
DeClue, JE .
ONCOGENE, 2000, 19 (54) :6306-6316
[3]
Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a [J].
Castrillon, DH ;
Miao, LL ;
Kollipara, R ;
Horner, JW ;
DePinho, RA .
SCIENCE, 2003, 301 (5630) :215-218
[4]
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome [J].
Corradetti, MN ;
Inoki, K ;
Bardeesy, N ;
DePinho, RA ;
Guan, KL .
GENES & DEVELOPMENT, 2004, 18 (13) :1533-1538
[5]
Craparo A, 1997, J BIOL CHEM, V272, P11663
[6]
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression [J].
Fingar, DC ;
Blenis, J .
ONCOGENE, 2004, 23 (18) :3151-3171
[7]
Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues [J].
Furuyama, T ;
Nakazawa, T ;
Nakano, I ;
Mori, N .
BIOCHEMICAL JOURNAL, 2000, 349 :629-634
[8]
Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling [J].
Gao, XS ;
Zhang, Y ;
Arrazola, P ;
Hino, O ;
Kobayashi, T ;
Yeung, RS ;
Ru, BG ;
Pan, DJ .
NATURE CELL BIOLOGY, 2002, 4 (09) :699-704
[9]
TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth [J].
Gao, XS ;
Pan, DJ .
GENES & DEVELOPMENT, 2001, 15 (11) :1383-1392
[10]
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 [J].
Garami, A ;
Zwartkruis, FJT ;
Nobukuni, T ;
Joaquin, M ;
Roccio, M ;
Stocker, H ;
Kozma, SC ;
Hafen, E ;
Bos, JL ;
Thomas, G .
MOLECULAR CELL, 2003, 11 (06) :1457-1466